| Outcome Measures: |
Primary: Incidence of Serious Adverse Reactions, Including Major Hypoglycaemic Events, The incidence of serious adverse reactions (SARs), including major hypoglycaemic events, during 3 months of insulin detemir therapy for all countries participating in the study, and during 6 and 12 months of insulin detemir therapy for some of the participating countries. The three sub-groups were mutually exclusive. Physicians did not report all major hypoglycaemic events as SARs. The values in the SAE table are SARs including only those major hypoglycaemic events that were reported as SARs by physicians., Months 0-12 |
|
| Locations: |
Novo Nordisk Investigational Site, Brussels, 1070, Belgium|Novo Nordisk Investigational Site, Prague, 16000, Czech Republic|Novo Nordisk Investigational Site, Copenhagen S, 2300, Denmark|Novo Nordisk Investigational Site, Espoo, FI-02600, Finland|Novo Nordisk Investigational Site, Paris La défense cedex, 92932, France|Novo Nordisk Investigational Site, Vouliagment, 16671, Greece|Novo Nordisk Investigational Site, Dublin 2, Ireland|Novo Nordisk Investigational Site, Kfar Saba, 44425, Israel|Novo Nordisk Investigational Site, Rome, 00144, Italy|Novo Nordisk Investigational Site, Seoul, 137-920, Korea, Republic of|Novo Nordisk Investigational Site, Malmö, 202 15, Sweden|Novo Nordisk Investigational Site, Istanbul, 34335, Turkey|Novo Nordisk Investigational Site, Crawley, RH11 9RT, United Kingdom
|
